Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.

ABSTRACT: Metastatic and relapsed osteosarcoma remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells are in their nascent stage but remain a viable therapeutic strategy for patients with aggressive solid tumors such as osteosarcoma. Folate receptor-α (FOLR1) has been functionally implicated in osteosarcoma pathophysiology, providing rationale as a potential therapeutic target. We recently advanced a FOLR1-specific CAR T-cell product (FH FOLR1-CART) into a trial in infant acute myeloid leukemia (NCT06609928) and now evaluate this CAR construct against osteosarcoma. We provide comprehensive FOLR1 transcript and protein expression profile in patients with osteosarcoma, c

SUBMITTER: Choe M 

PROVIDER: S-EPMC12455178 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature